A Phase 4 interventional study of Anticoagulation with heparin and EkoSonicTM Endovascular System in Pulmonary Embolism, sponsored by Boston Scientific Corporation. Completed at 60 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Boston Scientific Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Pulmonary Embolism with a site in United States — 34 open to participants now, 43 under way, 6 of them phase 3. Pulmonary Embolism · United States.
Among the 236 studies in Pulmonary Embolism with a site in United States, this one is the 41st largest by enrollment of the 166 interventional ones that give a count, is one of 10 that started in 2021, is one of 21 in phase 4, and was the 170th registered.
833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.
Browse Pulmonary Embolism studies →34 of the 236 studies in Pulmonary Embolism with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Bulgaria, Japan and 2 more countries
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 21+
Brigham and Women's Hospital · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Canada
Ages 18+
Angiodynamics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 17 · Phase 3 38 · Phase 4 21
First in 1999; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 544 is above the median of 174 across 430 interventional studies indexed under Pulmonary Embolism.
Median enrollment 142 across the 166 interventional studies, 286 across the 68 observational. Of the 169 that completed or were terminated, 76 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
78 of 236 have an industry lead sponsor. The 10 most frequent:
Boston Scientific Corporation is the lead sponsor of 528 studies on the registry; 40 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 57 (88%) have results posted.
Boston Scientific Corporation has 8 studies filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
17 of the studies in Pulmonary Embolism with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05591118Phase 3NYU Langone HealthPulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy | 2027-03-29 |
| NCT07213778Phase 3Regeneron PharmaceuticalsREGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | 2027-05-17 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
| NCT04798261Penumbra Inc.Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 236 studies in Pulmonary Embolism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There are many available treatments for pulmonary embolism (PE), but the best treatment for this condition is not known. The HI-PEITHO study will compare two treatment options that are both available on the market for the treatment of PE.
Patients will be randomized 1:1 to receive either blood thinners (anticoagulation) or blood thinners (anticoagulation) in combination with a device called the EkoSonicTM Endovascular device to dissolve blood clots. Patients will be followed for 12 months after randomization and have assessments while in the hospital as well as at 7 days, 30 days, 6 months and 12 months after randomization. The study will try to find out if one of these treatments is better than the other at reducing the risk of death and other serious problems.
This study will assess whether ultrasound-facilitated, catheter-directed thrombolysis and standard anticoagulation are associated with a significant reduction in the composite outcome of pulmonary embolism (PE)-related mortality, cardiorespiratory decompensation or collapse, or nonfatal symptomatic and objectively confirmed recurrence of PE compared to anticoagulation alone within seven days of randomization
The HI-PEITHO study has been designed to address the important gaps in clinical evidence by comparing the clinical benefit of the ultrasound-facilitated local delivery of a low dose thrombolytic agent and anticoagulation with those of anticoagulation alone in patients with intermediate-high risk PE at a higher estimated risk of early decompensation based on clinical parameters at presentation.
This study has a focus on improving the safety of thrombolysis and advancing the concept of intermediate-high risk and the PE severity criteria, to better identify patients who may clinically benefit from thrombolysis.
The results of this study will contribute further evidence to the existing data on the treatment and outcomes of acute, intermediate-high risk PE and provide controlled data related to catheter-based interventions.
Data will be entered by the site into an electronic database. The database will include data checks to compare data entered into the database against predefined rules for ranges and consistency with other data fields in the database.
Site monitoring will take place with source data verification to assess the accuracy and completeness of registry data by comparing the data to medical records and study assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Elevated risk of early death/hemodynamic collapse, indicated by at least two of the following new-onset clinical criteria:
Exclusion Criteria:
Hemodynamic instability*, i.e. at least one of the following present:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
Drug: Anticoagulation with heparin
Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) and EkoSonicTM Endovascular System \[ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg\]
Drug: Anticoagulation with heparin · Device: EkoSonicTM Endovascular System
Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
Also known as: heparin, LMWH, UFH, anticoag, antiplatelet
EkoSonicTM Endovascular System \[ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg\]
Also known as: EKOS, USCDT, CDT, thrombolysis, fibrinolysis
Number of Participants With PE-Related Mortality
Death resulting from pulmonary embolism occurring within the assessment period.
Time frame: Within seven days of randomization
Number of Participants With Recurrent Pulmonary Embolism
Symptomatic, objectively confirmed, nonfatal recurrent pulmonary embolism occurring during the assessment period.
Time frame: Within seven days of randomization
Number of Participants With Cardiorespiratory Decompensation or Collapse
Cardiorespiratory collapse or decompensation is defined as at least one of the following criteria: 1. cardiac arrest or need for CPR at any time between randomization and day 7; 2. signs of shock: new-onset persistent arterial hypotension (systolic blood pressure (SBP) below 90 mmHg or SBP drop by at least 40 mm Hg, over at least 15 minutes and despite an adequate volume status; or need for vasopressors to maintain SBP of at least 90 mmHg), accompanied by end-organ hypoperfusion (altered mental status; oliguria/anuria; or increased serum lactate) at any time between randomization and day 7; 3. placement on extracorporeal membrane oxygenation (ECMO) at any time between randomization and day 7; 4. intubation, or initiation of noninvasive mechanical ventilation at any time between randomization and day 7; 5. National Early Warning Score (NEWS) of 9 or higher, between 24 hours and 7 days after randomization, confirmed on consecutive measurements taken twice, 15 minutes apart.
Time frame: Within seven days of randomization
Change From Baseline in Right Ventricular-to-Left Ventricular (RV-to-LV) Diameter Ratio
The RV-to-LV diameter ratio was assessed by echocardiography at baseline and 48 hours after the index procedure. The ratio was calculated by dividing the right ventricular diameter by the left ventricular diameter. Change from baseline was defined as the difference between the 48-hour and baseline measurements. Higher RV-to-LV ratios indicate greater right ventricular dilation, whereas lower ratios indicate less right ventricular dilation and improvement in right ventricular size relative to the left ventricle.
Time frame: Baseline and 48 hours after the index procedure
Number of Participants With Cardiorespiratory Decompensation
The number of participants who experienced cardiorespiratory decompensation within 7 days of randomization. Cardiorespiratory decompensation was defined as the occurrence of any of the following: cardiac arrest or receipt of cardiopulmonary resuscitation (CPR), signs of shock, placement on extracorporeal membrane oxygenation (ECMO), intubation or initiation of non-invasive mechanical ventilation, or a National Early Warning Score (NEWS) of 9 or greater. Participants were counted once if they experienced one or more of these events during the 7-day assessment period.
Time frame: Within seven days of randomization
Number of Participants With GUSTO Major (Moderate or Severe) Bleeding
Major bleeding will be adjudicated according to the GUSTO criteria: 1. GUSTO severe or life-threatening bleeding: A bleeding episode that leads to hemodynamic compromise requiring emergency intervention (such as replacement of fluid and/or blood products, inotropic support, or surgical treatment), or is life-threatening or fatal. 2. GUSTO moderate bleeding (a bleeding episode requiring blood transfusion(s), but which is not deemed life-threatening and does not lead to hemodynamic compromise requiring emergency fluid replacement, inotropic support, or interventional treatment).
Time frame: Within seven days of randomization
Number of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding
Major bleeding will also be adjudicated according to the ISTH criteria: 1. Fatal bleeding and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome) and/or 3. Bleeding causing a fall in hemoglobin level of 20 g/L (2 g/dL) or more, or leading to transfusion of two or more units of whole blood or red blood cells.
Time frame: Within 7 days, 30 days, and 6 months of randomization
Number of Participants With Ischemic or Hemorrhagic Stroke
Occurrence of ischemic or hemorrhagic stroke during the assessment period. Participants were counted once for each assessment time point if an ischemic or hemorrhagic stroke occurred.
Time frame: Within 7 days and 30 days following randomization
Number of Participants With All-Cause Mortality
Death from any cause.
Time frame: Within 7 days, 30 days, 6 months, and 12 months of randomization
Number of Participants With at Least One Serious Adverse Event
Number of participants who experienced at least one serious adverse event.
Time frame: Within 30 days of randomization
Number of Participants With All-Cause Mortality, Cardiorespiratory Collapse or Decompensation, or Recurrent Pulmonary Embolism
Death due to any cause, Cardiorespiratory collapse or decompensation should fulfill at least one of the following criteria: 1. cardiac arrest or need for CPR at any time between randomization and day 7; 2. signs of shock: new-onset persistent arterial hypotension (SBP below 90 mmHg or SBP drop by at least 40 mmHg over at least 15 minutes, and despite an adequate filling status; or need for vasopressors to maintain SBP of at least 90 mmHg), accompanied by end-organ hypoperfusion (altered mental status; oliguria/anuria; or increased serum lactate) at any time between randomization and day 7; 3. placement on ECMO at any time between randomization and day 7; 4. intubation, or initiation of non-invasive mechanical ventilation at any time between randomization and day 7; 5. National Early Warning Score (NEWS) of 9 or higher, between 24 hours and 7 days after randomization, confirmed on consecutive measurements, taken twice.
Time frame: Within 30 days of randomization
Number of Participants With Symptomatic Recurrent Pulmonary Embolism
Number of participants who experienced symptomatic recurrent pulmonary embolism.
Time frame: Within 30 days and 6 months of randomization
Change From Baseline in RV Dysfunction on Echocardiography
Right ventricle to left ventricle end diastolic diameter ratio (RV/LV).
Time frame: 6 months
Duration of Hospitalization for the Index Pulmonary Embolism Event
Length of hospital stay was calculated as the number of days between hospital admission and hospital discharge.
Time frame: Within 30 days of randomization
Duration of Stay in the Intensive Care Unit (ICU), Intermediate Care Unit, or Coronary Care Unit for the Index Pulmonary Embolism Event
Length of stay was calculated as the time between admission to and discharge from the intensive care unit (ICU), intermediate care unit, or coronary care unit during hospitalization.
Time frame: Within 30 days of randomization
Functional Status as Measured by World Health Organization (WHO) Functional Class
WHO Functional Class categorizes symptom severity and physical activity limitation. Class I indicates no limitation of physical activity; Class II indicates slight limitation of physical activity; Class III indicates marked limitation of physical activity; and Class IV indicates inability to perform physical activity without symptoms, with symptoms that may be present at rest. Lower classes (I-II) represent better functional status, whereas higher classes (III-IV) represent worse functional status. Participants were classified according to WHO Functional Class at each assessment time point.
Time frame: Up to 7 days, 30 days, 6 and 12 months of randomization
Functional Status as Measured by 6-Minute Walk Test (6MWT)
The 6MWT measures the distance a patient can walk on a flat surface in a period of 6 minutes. A 100-meter distance is measured in a hallway, and the patient is asked to walk quickly as many laps as they can over the course of the timed test. Greater distances indicate better functional exercise capacity, whereas shorter distances indicate greater functional limitation. The total distance is measured. The patient's baseline vitals and symptoms are compared to their condition at the completion of the test.
Time frame: 30 days, 6 months, and 12 months of randomization
Functional Status as Measured by Post-Venous Thromboembolism Functional Status (PVFS) Scale
The Post-Venous Thromboembolism Functional Status (PVFS) Scale assesses functional limitations following a venous thromboembolic event. Participants are classified according to the following grades: Grade 0 = no functional limitations or symptoms; Grade 1 = symptoms present but no limitations in usual activities; Grade 2 = slight functional limitations requiring occasional modification of activities; Grade 3 = moderate functional limitations requiring regular modification of activities; Grade 4 = severe functional limitations with inability to perform usual activities without assistance; Grade 5 = death. Lower grades (0-1) indicate better functional status and less disability, while higher grades (3-4) indicate worse functional status and greater disability. Participants were assessed at each study time point and classified according to the PVFS grade that best described their functional status.
Time frame: 30 days, 6 months, and 12 months of randomization
Quality of Life Using PEmb-QOL
PEmb-QOL is a questionnaire that assesses post-pulmonary embolism quality of life in the context of pulmonary-specific symptoms. The PEmb-QOL questionnaire contains six dimensions based on the contents of the items: frequency of complaints, limitations in activities of daily living, work-related problems, social limitations, intensity of complaints and emotional complaints. Higher scores indicate worse outcome.
Time frame: 6 and 12 months
Quality of Life Using SF-36
The SF-36 questionnaire is a generic quality of life measure containing eight health domains (physical functioning, physical role, pain, general health, vitality, social function, emotional role functioning, and mental health). The scoring is on a 0-100 scale, with a higher score indicating better health. Scores are combined into two overall summary scores: physical health summary score and mental health summary score.
Time frame: 6 and 12 months
Quality of Life Using EQ-5D Scale
The EQ-5D is a patient reported outcome that provides a simple descriptive profile and single index value for health status. The questionnaire consists of 5 questions pertaining to specific health dimensions, including mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and overall health status rating scale.
Time frame: 6 and 12 months
Diagnosis of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
CTEPH will be diagnosed by the investigational site according to presence of all of the following criteria: 1. At least one mismatched segmental perfusion defect demonstrated by ventilation/perfusion scanning after 3 months of adequate therapeutic anticoagulation 2. Resting mean pulmonary arterial pressure (mPAP) ≥25 mmHg measured by invasive right heart catheterization 3. Pulmonary capillary wedge pressure ≤15 mmHg.
Time frame: Within 12 months
| Milestone | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Started | 271 | 273 |
| Completed | 266 | 266 |
| Not completed | 5 | 7 |
| Milestone | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Started | 271 | 273 |
| Completed | 250 | 253 |
| Not completed | 21 | 20 |
Death resulting from pulmonary embolism occurring within the assessment period.
| Participants | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Number of Participants With PE-Related Mortality | 1 | 3 |
Symptomatic, objectively confirmed, nonfatal recurrent pulmonary embolism occurring during the assessment period.
| Participants | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Number of Participants With Recurrent Pulmonary Embolism | 1 | 1 |
Cardiorespiratory collapse or decompensation is defined as at least one of the following criteria: 1. cardiac arrest or need for CPR at any time between randomization and day 7; 2. signs of shock: new-onset persistent arterial hypotension (systolic blood pressure (SBP) below 90 mmHg or SBP drop by at least 40 mm Hg, over at least 15 minutes and despite an adequate volume status; or need for vasopressors to maintain SBP of at least 90 mmHg), accompanied by end-organ hypoperfusion (altered mental status; oliguria/anuria; or increased serum lactate) at any time between randomization and day 7; 3. placement on extracorporeal membrane oxygenation (ECMO) at any time between randomization and day 7; 4. intubation, or initiation of noninvasive mechanical ventilation at any time between randomization and day 7; 5. National Early Warning Score (NEWS) of 9 or higher, between 24 hours and 7 days after randomization, confirmed on consecutive measurements taken twice, 15 minutes apart.
| Participants | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Number of Participants With Cardiorespiratory Decompensation or Collapse | 28 | 10 |
The RV-to-LV diameter ratio was assessed by echocardiography at baseline and 48 hours after the index procedure. The ratio was calculated by dividing the right ventricular diameter by the left ventricular diameter. Change from baseline was defined as the difference between the 48-hour and baseline measurements. Higher RV-to-LV ratios indicate greater right ventricular dilation, whereas lower ratios indicate less right ventricular dilation and improvement in right ventricular size relative to the left ventricle.
| Ratio | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Change From Baseline in Right Ventricular-to-Left Ventricular (RV-to-LV) Diameter Ratio | -0.27 ± .23 | -0.38 ± 0.24 |
The number of participants who experienced cardiorespiratory decompensation within 7 days of randomization. Cardiorespiratory decompensation was defined as the occurrence of any of the following: cardiac arrest or receipt of cardiopulmonary resuscitation (CPR), signs of shock, placement on extracorporeal membrane oxygenation (ECMO), intubation or initiation of non-invasive mechanical ventilation, or a National Early Warning Score (NEWS) of 9 or greater. Participants were counted once if they experienced one or more of these events during the 7-day assessment period.
| Participants | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Cardiac arrest or cardiopulmonary resuscitation | 4 | 6 |
| Signs of shock | 9 | 5 |
| Placement on ECMO | 3 | 1 |
| Intubation or non-invasive mechanical ventilation | 5 | 6 |
| National Early Warning Score ≥9 | 19 | 2 |
Major bleeding will be adjudicated according to the GUSTO criteria: 1. GUSTO severe or life-threatening bleeding: A bleeding episode that leads to hemodynamic compromise requiring emergency intervention (such as replacement of fluid and/or blood products, inotropic support, or surgical treatment), or is life-threatening or fatal. 2. GUSTO moderate bleeding (a bleeding episode requiring blood transfusion(s), but which is not deemed life-threatening and does not lead to hemodynamic compromise requiring emergency fluid replacement, inotropic support, or interventional treatment).
| Participants | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Number of Participants With GUSTO Major (Moderate or Severe) Bleeding | 4 | 9 |
Major bleeding will also be adjudicated according to the ISTH criteria: 1. Fatal bleeding and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome) and/or 3. Bleeding causing a fall in hemoglobin level of 20 g/L (2 g/dL) or more, or leading to transfusion of two or more units of whole blood or red blood cells.
Results for this outcome have not been posted.
Occurrence of ischemic or hemorrhagic stroke during the assessment period. Participants were counted once for each assessment time point if an ischemic or hemorrhagic stroke occurred.
| Participants | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Ischemic Stroke within 7 days | 0 | 1 |
| Ischemic Stroke within 30 days | 0 | 1 |
| Intracranial hemorrhage within 7 days | 0 | 0 |
| Intracranial hemorrhage within 30 days | 0 | 0 |
Death from any cause.
Results for this outcome have not been posted.
Number of participants who experienced at least one serious adverse event.
| Participants | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Number of Participants With at Least One Serious Adverse Event | 44 | 42 |
Death due to any cause, Cardiorespiratory collapse or decompensation should fulfill at least one of the following criteria: 1. cardiac arrest or need for CPR at any time between randomization and day 7; 2. signs of shock: new-onset persistent arterial hypotension (SBP below 90 mmHg or SBP drop by at least 40 mmHg over at least 15 minutes, and despite an adequate filling status; or need for vasopressors to maintain SBP of at least 90 mmHg), accompanied by end-organ hypoperfusion (altered mental status; oliguria/anuria; or increased serum lactate) at any time between randomization and day 7; 3. placement on ECMO at any time between randomization and day 7; 4. intubation, or initiation of non-invasive mechanical ventilation at any time between randomization and day 7; 5. National Early Warning Score (NEWS) of 9 or higher, between 24 hours and 7 days after randomization, confirmed on consecutive measurements, taken twice.
| Participants | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Number of Participants With All-Cause Mortality, Cardiorespiratory Collapse or Decompensation, or Recurrent Pulmonary Embolism | 30 | 12 |
Number of participants who experienced symptomatic recurrent pulmonary embolism.
Results for this outcome have not been posted.
Right ventricle to left ventricle end diastolic diameter ratio (RV/LV).
Results for this outcome have not been posted.
Length of hospital stay was calculated as the number of days between hospital admission and hospital discharge.
| Mean number of days | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Duration of Hospitalization for the Index Pulmonary Embolism Event | 6.48 ± 4.88 | 5.77 ± 5.02 |
Length of stay was calculated as the time between admission to and discharge from the intensive care unit (ICU), intermediate care unit, or coronary care unit during hospitalization.
| Mean number of days | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Duration of Stay in the Intensive Care Unit (ICU), Intermediate Care Unit, or Coronary Care Unit for the Index Pulmonary Embolism Event | 2.78 ± 3.09 | 2.19 ± 3.02 |
WHO Functional Class categorizes symptom severity and physical activity limitation. Class I indicates no limitation of physical activity; Class II indicates slight limitation of physical activity; Class III indicates marked limitation of physical activity; and Class IV indicates inability to perform physical activity without symptoms, with symptoms that may be present at rest. Lower classes (I-II) represent better functional status, whereas higher classes (III-IV) represent worse functional status. Participants were classified according to WHO Functional Class at each assessment time point.
Results for this outcome have not been posted.
The 6MWT measures the distance a patient can walk on a flat surface in a period of 6 minutes. A 100-meter distance is measured in a hallway, and the patient is asked to walk quickly as many laps as they can over the course of the timed test. Greater distances indicate better functional exercise capacity, whereas shorter distances indicate greater functional limitation. The total distance is measured. The patient's baseline vitals and symptoms are compared to their condition at the completion of the test.
Results for this outcome have not been posted.
The Post-Venous Thromboembolism Functional Status (PVFS) Scale assesses functional limitations following a venous thromboembolic event. Participants are classified according to the following grades: Grade 0 = no functional limitations or symptoms; Grade 1 = symptoms present but no limitations in usual activities; Grade 2 = slight functional limitations requiring occasional modification of activities; Grade 3 = moderate functional limitations requiring regular modification of activities; Grade 4 = severe functional limitations with inability to perform usual activities without assistance; Grade 5 = death. Lower grades (0-1) indicate better functional status and less disability, while higher grades (3-4) indicate worse functional status and greater disability. Participants were assessed at each study time point and classified according to the PVFS grade that best described their functional status.
Results for this outcome have not been posted.
PEmb-QOL is a questionnaire that assesses post-pulmonary embolism quality of life in the context of pulmonary-specific symptoms. The PEmb-QOL questionnaire contains six dimensions based on the contents of the items: frequency of complaints, limitations in activities of daily living, work-related problems, social limitations, intensity of complaints and emotional complaints. Higher scores indicate worse outcome.
Results for this outcome have not been posted.
The SF-36 questionnaire is a generic quality of life measure containing eight health domains (physical functioning, physical role, pain, general health, vitality, social function, emotional role functioning, and mental health). The scoring is on a 0-100 scale, with a higher score indicating better health. Scores are combined into two overall summary scores: physical health summary score and mental health summary score.
Results for this outcome have not been posted.
The EQ-5D is a patient reported outcome that provides a simple descriptive profile and single index value for health status. The questionnaire consists of 5 questions pertaining to specific health dimensions, including mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and overall health status rating scale.
Results for this outcome have not been posted.
CTEPH will be diagnosed by the investigational site according to presence of all of the following criteria: 1. At least one mismatched segmental perfusion defect demonstrated by ventilation/perfusion scanning after 3 months of adequate therapeutic anticoagulation 2. Resting mean pulmonary arterial pressure (mPAP) ≥25 mmHg measured by invasive right heart catheterization 3. Pulmonary capillary wedge pressure ≤15 mmHg.
Results for this outcome have not been posted.
Collected over Through 30 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anticoagulation | 3/271 (1.1%) | 44/271 (16.2%) | 6/271 (2.2%) |
| Anticoagulation and EkoSonicTM Endovascular System | 6/273 (2.2%) | 42/273 (15.4%) | 16/273 (5.9%) |
| Event | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| Cardiopulmonary failureCardiac disorders | 12/271 | 2/273 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/271 | 4/273 |
| Haemodynamic instabilityVascular disorders | 4/271 | 1/273 |
| PneumoniaInfections and infestations | 4/271 | 3/273 |
| Cardiac arrestCardiac disorders | 2/271 | 2/273 |
| Cardio-respiratory arrestCardiac disorders | 2/271 | 1/273 |
| HypotensionVascular disorders | 2/271 | 1/273 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/271 | 0/273 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/271 | 0/273 |
| Atrial fibrillationCardiac disorders | 2/271 | 1/273 |
| Event | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 3/271 | 0/273 |
| Catheter site haemorrhageGeneral disorders | 0/271 | 2/273 |
| Vascular access site haematomaInjury, poisoning and procedural complications | 0/271 | 2/273 |
| HaematomaVascular disorders | 0/271 | 2/273 |
| HaematuriaRenal and urinary disorders | 0/271 | 2/273 |
| Puncture site haemorrhageGeneral disorders | 1/271 | 0/273 |
| DizzinessNervous system disorders | 1/271 | 0/273 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/271 | 1/273 |
| C-reactive protein increasedInvestigations | 1/271 | 0/273 |
| Splenic infarctionBlood and lymphatic system disorders | 0/271 | 1/273 |
| Age, Customized(Years) | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System | Total |
|---|---|---|---|
| Age (years) | 58.2 ± 13.4 | 58.2 ± 13.6 | 58.2 ± 13.5 |
| Sex: Female, Male(Participants) | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System | Total |
|---|---|---|---|
| Female | 118 | 114 | 232 |
| Male | 153 | 159 | 312 |
| Race/Ethnicity, Customized(Participants) | Anticoagulation | Anticoagulation and EkoSonicTM Endovascular System | Total |
|---|---|---|---|
| Asian | 4 | 4 | 8 |
| Black | 39 | 23 | 62 |
| Hispanic/Latino ethnic group | 8 | 6 | 14 |
| Native Hawaiian or other Pacific Islander | 2 | 4 | 6 |
| White | 211 | 232 | 443 |
| Unknown | 12 | 6 | 18 |
| Other | 3 | 4 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Jul 2025, 47 months.
Results were first posted in Nov 2026, 1 year 3 months after primary completion.
Of 24 phase 4 interventional studies under Pulmonary Embolism, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 82. This study's 47 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston Scientific Corporation →